We are live on ! Find out more
CS

Candriam SCA Portfolio holdings

AUM $19.3B
1-Year Est. Return 39.18%
This Fund
S&P 500
This Quarter Est. Return
+16.29%
1 Year Est. Return
+39.18%
3 Year Est. Return
+109.85%
5 Year Est. Return
+149.31%
10 Year Est. Return
+617.16%
AUM
$7.82B
AUM Growth
+$1.31B
Cap. Flow
+$158M
Cap. Flow %
2.03%
Top 10 Hldgs %
19.27%
Holding
869
New
65
Increased
350
Reduced
240
Closed
81

Top Buys

Rank Stock Value
1
MRK icon
Merck
MRK
+$43.7M
2
BMY icon
Bristol-Myers Squibb
BMY
+$30.4M
3
GILD icon
Gilead Sciences
GILD
+$28.3M
4
BIIB icon
Biogen
BIIB
+$26.7M
5
GOOGL icon
Alphabet (Google) Class A
GOOGL
+$25.2M

Top Sells

Rank Stock Value
1
CELG
Celgene Corp
CELG
+$75.2M
2
LOXO
Loxo Oncology, Inc
LOXO
+$28.1M
3
DHR icon
Danaher
DHR
+$27.9M
4
A icon
Agilent Technologies
A
+$26.4M
5
MKC icon
McCormick & Company Non-Voting
MKC
+$18M

Sector Composition

Rank Sector Weight
1 Healthcare 33.36%
2 Technology 15.96%
3 Financials 11.25%
4 Consumer Discretionary 8.98%
5 Communication Services 7.83%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ARAY icon
601
Accuray
ARAY
$26.8M
$1.04M 0.01%
218,191
+135,338
+163% +$616K
MKL icon
602
Markel Group
MKL
$25.2B
$1.03M 0.01%
1,035
-227
-18% -$231K
VER
603
DELISTED
VEREIT, Inc.
VER
$1.03M 0.01%
24,586
+880
+4% +$35.1K
AUPH icon
604
Aurinia Pharmaceuticals
AUPH
$1.96B
$1.02M 0.01%
157,500
– –
TRI icon
605
Thomson Reuters
TRI
$42.7B
$1.02M 0.01%
16,427
+2,236
+16% +$125K
EXPE icon
606
Expedia Group
EXPE
$33.4B
$1.02M 0.01%
8,599
+1,295
+18% +$157K
TRU icon
607
TransUnion
TRU
$14.9B
$1.02M 0.01%
15,248
+3,095
+25% +$192K
WBD icon
608
Warner Bros
WBD
$63.4B
$1.02M 0.01%
37,604
-7,565
-17% -$210K
PPLI
609
People Inc
PPLI
$3.15B
$1.01M 0.01%
26,959
-182,477
-87% -$6.75M
KEYS icon
610
Keysight
KEYS
$53.6B
$1.01M 0.01%
+11,545
New +$896K
NGG icon
611
National Grid
NGG
$81.6B
$1M 0.01%
20
-1
-5% -$48
RDNT icon
612
RadNet
RDNT
$4.84B
$1M 0.01%
+80,792
New +$1.06M
JLL icon
613
Jones Lang LaSalle
JLL
$15.5B
$999K 0.01%
+6,480
New +$975K
ACGL icon
614
Arch Capital
ACGL
$36.3B
$995K 0.01%
30,781
– –
HAS icon
615
Hasbro
HAS
$12.8B
$994K 0.01%
+11,690
New +$1.02M
MRVL icon
616
Marvell Technology
MRVL
$170B
$993K 0.01%
49,943
-5,101
-9% -$95.3K
EXPD icon
617
Expeditors International
EXPD
$22.4B
$992K 0.01%
13,075
– –
BNFT
618
DELISTED
Benefitfocus, Inc.
BNFT
$990K 0.01%
20,000
– –
VRAY
619
DELISTED
ViewRay, Inc.
VRAY
$982K 0.01%
132,857
+122,675
+1,205% +$946K
CB icon
620
Chubb
CB
$139B
$981K 0.01%
7
+1
+17% +$133
MHK icon
621
Mohawk Industries
MHK
$7.05B
$975K 0.01%
7,732
+170
+2% +$22.1K
WYNN icon
622
Wynn Resorts
WYNN
$10.3B
$973K 0.01%
8,155
+1,087
+15% +$130K
XENT
623
DELISTED
Intersect ENT, Inc
XENT
$965K 0.01%
30,000
– –
SCI icon
624
Service Corp International
SCI
$11.4B
$956K 0.01%
23,798
-261,015
-92% -$10.9M
STLD icon
625
Steel Dynamics
STLD
$36.1B
$948K 0.01%
26,885
+66
+0.2% +$2.35K
23 24
25
26 27

Similar funds

PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
A
AustralianSuper Melbourne, Australia $19.2B AUM 31.95% 1-Year Est. Return
MGP
M&G plc London, United Kingdom $19.4B AUM 16.7% 1-Year Est. Return
LF
Lansforsakringar Fondforvaltning Stockholm, Sweden $19.1B AUM 26.9% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $19.5B AUM 17.33% 1-Year Est. Return
SOMRS
State of Michigan Retirement System Lansing, Michigan $18.9B AUM 27.96% 1-Year Est. Return
BPA
Beacon Pointe Advisors Newport Beach, California $18.9B AUM 18.9% 1-Year Est. Return
MIM
MetLife Investment Management Whippany, New Jersey $19.6B AUM 32.64% 1-Year Est. Return

Candriam SCA's Q1 2019 Portfolio in Review

As of Q1 2019, Candriam SCA held 869 positions worth $7.82B, up 20% from $6.51B the previous quarter. Its ten largest holdings account for 19% of the portfolio.

Candriam SCA's Q1 2019 filing shows 65 new, 350 increased, 240 reduced and 81 closed positions. Its largest new stake was Baozun: 640,000 shares worth $26.6M. The largest sale was Celgene Corp, an estimated $75.2M.

By sector, the portfolio is most concentrated in Healthcare at 33% of assets, down from 35% a quarter earlier, followed by Technology and Financials.

  • Candriam SCA's largest Q1 2019 buy was Baozun: 640,000 shares worth $26.6M.
  • Candriam SCA added most to Merck in Q1 2019, an estimated $43.7M increase.
  • Candriam SCA's biggest Q1 2019 reduction was Celgene Corp, cutting an estimated $75.2M.
  • Candriam SCA fully exited Loxo Oncology, Inc in Q1 2019, selling an estimated $28.1M.
  • Candriam SCA's ten largest holdings make up 19% of its $7.82B portfolio in Q1 2019.
  • Candriam SCA opened 65 new positions and closed 81 in Q1 2019.
  • Candriam SCA's portfolio value rose 20% quarter-over-quarter to $7.82B.

Based on Candriam SCA's 13F filing for Q1 2019, filed 2 May 2019.